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Malte Heeg1, Alexander Mertens1, David Ellenberger2, Gerhard A Müller1 and Daniel Patschan1*Abstract
Background: AKI significantly worsens prognosis of hospitalized patients. This is particularly the case in patients
with sepsis. The risk for aquiring sepsis is significantly increased in malignant diseases. Aim of the present
retrospective study was to analyze outcomes of tumor patients with sepsis and AKI.
Methods: One-thousand and seventeen patients, treated at the ICU of the Department of Nephrology and
Rheumatology of the University Hospital Göttingen from 2009 to 2011 were retrospectively analyzed for mortality,
sepsis, AKI, need for renal replacement therapy (dialysis) and malignancies.
Results: AKI occurred significantly more frequent in septic than in non-septic patients and in tumor as oposed to
non-tumor patients. Mortaliy rates were higher in the respective latter groups. Mortality increased even further if
patients suffered from a malignant disease with sepsis and AKI. Mortality rates peaked if dialysis treatment became
mandatory. In non-solid tumors 100% of the patients died if they suffered drom sepsis and AKI. This was not the
case in solid malignancies (mortality rate 56%).
Conclusions: We conclude that prognosis of tumor patients with AKI and sepsis is very poor. Mortality increases to
almost 70% if diaylsis therapy is initiated. Non-solid tumors are associated with a 100% mortality if sepsis and AKI
conincide.
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Acute kidney injury is one of the major problems in to-
day’s clinical medicine. Approximately 1-5% of all hospi-
talized patients develop AKI during the course of the
treatment [1,2]. Prognosis has not substantially been im-
proved during the last 20–30 years since mortality rates
still vary between 30-50% [3]. The poor prognosis is not
exclusively induced by AKI per se but does also result
from the underlying causes / diseases leading to the de-
cline in kidney function [4]. This is particularly the case
with conditions that compromize oxygen and nutrient
supply of the whole organism. Among those are heart
failure and sepsis. Especially the latter has been identi-
fied as one of the most potent risk factors for AKI
during intensive care treatment [5,6]. According to
newer data, about 50% of all sepsis patients treated at
the ICU suffer from AKI of various severity. The average* Correspondence: d.patschan@gmail.com
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reproduction in any medium, provided the ormortality in sepsis-associated AKI is 50%, even if dialysis
treatment has been initiated [7]. The risk for sepsis is
being increased by circumstances that affect the im-
munological response of the host. This typically occurs in
malignant diseases. The risk for infectious complications
in tumor patients is dramatically increased by bone
marrow-toxic chemotherapeutics. Cytotoxic treatment on
the other hand can also induce AKI, depending on the
type of drugs used for therapy. Maccariello and colleagues
analyzed the outcome of ICU patients requiring renal re-
placement therapy in a prospective manner [8]. The study
failed to show an association between mortality and can-
cer. Nevertheless, mortality was higher if patients suffered
from sepsis. The authors did not separately analyze sepsis
patients with a malignant disease.
Aim of the this retrospective observational single cen-
ter study was to analyze outcomes of ICU patients with
AKI. Thereby, our particular interest focused on mortal-
ity of AKI in malignancies with versus without sepsis.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Outcome characteristics
Variables Survivors Non-survivors p-value
Age 64.3 ±16.6 years 69.5 ±13.5 years <0.001
Male gender 440 (58%) 168 (64%) 0.066
SAPS II 30.4 ±10.7 41.8 ±10.9 <0.001
AKI 287 (37%) 148 (56%) <0.001
Sepsis 175 (23%) 156 (60%) <0.001
AKI+Sepsis 105 (16%) 117 (45%) <0.001
Cancer 135 (17%) 76 (29%) <0.001
Liver cirrhosis 52 (7%) 30 (12%) 0.017
Dialysis 224 (30%) 120 (46%) <0.001
ICU stay 7.4 ±8.1 days 7.4 ±8.4 days 0.9
Controlled ventilation 244 (32%) 185 (71%) <0.001
Table 1 compares frequencies of different variables / mortality risk factors
between survivors and non-survivors. The differences between the two groups
were significant in all analyzed categories, with the exception of male gender
and length of ICU stay. Table 1 shows frequencies of the three AKIN stages in
AKI patients if used for diagnosis, followed by the respective mean serum
creatinine concentrations at the time of admission to the ICU (results as
mean ±SEM).
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Patients and setting
The present investigation was a retrospective single-
centre analysis. All patients treated at the medical
intensive care unit of the department of nephrology
and rheumatology (University Hospital of Göttingen,
Germany) between 2009 and 2011 were included into
the study. It was formally approved by the local ethics
committee. Acute kidney injury was defined using the
AKIN criteria [9]. Patients with pre-existing ESRD
(end stage renal disease) were also included into the
study. In these patients, any further acute aggravation of
renal dysfunction was defined as AKI if the AKIN cri-
teria were applicable and / or if, for other reasons, dialy-
sis treatment was initiated. Indications for dialysis were
the presence of one or more of the following criteria: re-
fractory hyperkalemia, increases of serum creatinine >3
mg/dl and / or of blood urea nitrogen >100 mg/dl at any
given time point, and signs / symptoms of fluid overload
due to dimished urine output, respectively. As in earlier
studies [10], sepsis was defined as systemic inflammatory
response syndrome (SIRS) of infectious origin [11].
Thus, beside fulfilling the criteria of SIRS [12], all
patients showed at least once positive blood cultures for
either Gram-positive or Gram-negative bacteria and/or
clinical symptoms of an infectous disease. The term ma-
lignancy was used in any case of tumor manifestation at
the time of treatment at the ICU, regardless of the re-
spective stage of the disease. Thereby, we differentiated
between solid and non-solid (hemato-oncological) malig-
nancies. For further clinical characterization a number
of different parameters, such as c-reactive protein and
the SAPS (Simplified Acute Physiology Score) II scores
were documented on a daily basis. All data analyzed in
this study were extracted from a database, belonging to
the department of Nephrology & Rheumatology of the
University Hospital of Göttingen.
Statistical analysis
All results are expressed as percentages. Differences
between 3 or more groups were analyzed by ANOVA.
Differences between two groups were analyzed by chi-
square test. Significance was considered at p<0.05.
Results
Patients
A total of 1.017 patients were included into the study.
Six-hundred and eight were male, 409 were female, the
mean age of all patients was 65 ±16 years with 65 ±14
years in men and 66 ±18 years in women. All patients
were treated at the intensive care unit of the department
of nephrology and rheumatology of the university hos-
pital Göttingen (Germany) between 2009 and 2011. Sep-
sis was diagnosed in 330 patients (32% - 208 male [63%],122 female [37%]), 687 patients (68%) did not fulfill the
respective criteria. Two-hundred and twelve patients
(21% - 138 male [65%], 74 female [35%]) suffered from a
malignant disease at the time of admission to the ICU
(non-solid tumor: 88, solid tumor: 124). Thirty-three
patients with a non-solid tumor underwent bone
marrow-/stem cell transplantation in their history. Four-
hundred and thirty-five patients (43% - 278 male [64%],
157 female [36%]) either presented with AKI at the time
of ICU admission or developed AKI during the treatment
course at the ICU. Liver cirrhosis was diagnosed in 83
patients (8% - 57 male [69%], 25 female [31%]). The most
important general outcome parameters of all included
patients are summarized in Tables 1 and 2.AKI in sepsis
As pointed out earlier sepsis was diagnosed in 330 pa-
tients (32% - 208 male [63%], 122 female [37%]), 687 pa-
tients (68%) did not fulfill the respective criteria. In the
no sepsis group 474 patients (69%) did not develop AKI
while 213 (31%) presented with AKI of various severity.
One-hundred and eight patients (32%) in the sepsis
group did not suffer from AKI during the course of the
disease, but AKI developed in 222 individuals (68%).
Thus, AKI occured significantly more frequent in sepsis
than in non-septic patients (p<0.001). The mortality
rates within the respective groups were: no sepsis
without AKI - 15% (72/474), no sepsis with AKI – 15%
(31/213), sepsis without AKI – 36% (39/108), and sepsis
with AKI – 53% (117/222). Mortality rates were signifi-
cantly higher in patients with sepsis (± AKI) as com-
pared to those without sepsis (± AKI). Additionally,
Table 2 Serum creatinine concentrations in AKI patients
before onset of AKI
AKIN stage n [Creatinine]S before
onset of AKI (mg/dl)
1 27 1.3 ±0.1
2 14 2.4 ±0.3
3 95 3.7 ±0.2
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those wihtout AKI (Figure 1).
AKI in malignancies
Two-hundred and twelve patients (21% - 138 male
[65%], 74 female [35%]) suffered from a malignant dis-
ease at the time of admission to the ICU. A solid tumor
was diagnosed in 123 patients (58%) while a non-solid
tumor was apparent in 87 patients (42%). Incidences of
AKI were: patients without malignancy 329/805 (41%),
patients with a malignant disease (either solid or non-
solid tumor) 104/212 (49%). The difference was statisti-
cally significant (p=0.032). Mortalty rates were: patients
without tumor but with AKI 93/329 (28%), patients
with malignancy and AKI 53/104 (51%). The calculated
p-value was below 0.001. Thus, the coincidence of a
malignant disease and AKI dramatically worsened the
overall prognosis (Figure 2).
AKI in malignancies with sepsis
One-hundred and fifteen patients with a malignant dis-
ease did not suffer from sepsis (54% - 115/212). In this




























Figure 1 Mortality in septic versus non-septic patients with and witho
or without AKI, mortality was 15% in both groups (no AKI 72/474, AKI 31/2
without sepsis, independently from the presence of AKI (sepsis without AKmortality was 22% (8/35). Ninety-seven patients with a
malignancy were diagnosed with sepsis (46% - 97/212).
In this particular group, AKI occurred in 69% (67/97),
mortality was 67% (45/67). In both categories (incidence
of AKI, mortality) differences between the two groups
(tumor with vs. without sepsis) were significant (p-values
lower than 0.001 - Figure 3). In a subgroup analysis,
mortality rates of patients with sepsis and AKI were
compared, depending on the presence of a solid versus
non-solid tumor disease. As a matter of fact, patients
with a non-solid tumor died in 100% if sepsis and AKI
coincided, as compared to those with a solid tumor dis-
ease. In the latter group, mortality was 56% (p<0.001).
Mortality and dialysis
A total number of 341 patients required dialysis treatment.
Subgroup analysis revealed the following frequencies of
renal replacement therapy in patients with versus without
malignant diseases: patients without tumor and without
sepsis (28%) 94/341, mortality was 15% (14/94), patients
without tumor but with sepsis (28%) 95/341, mortality was
46% (44/95), patients with tumor and without sepsis 6%
(20/341), mortality was 20% (4/20), patients with tumor
plus sepsis 11% (36/341), mortality was 66% (24/36). The
following differences in mortality rates were statistically sig-
nificant between the groups: no tumor, no sepsis versus no
tumor, sepsis p<0.001, tumor, no sepsis versus tumor, sepsis
p<0.001, no tumor, sepsis versus tumor, sepsis p=0.037.
Discussion
Aim of this study was to retrospectively analyze epi-
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Figure 2 Incidence of AKI and mortality in tumor versus non-tumor patients. Incidences of AKI were: patients without malignancy 329/805
(41%), patients with a malignant disease (either solid or non-solid tumor) 104/212 (49%). The difference was statistically significant (p=0.032).
Mortalty rates were: patients without tumor but with AKI 93/329 (28%), patients with malignancy and AKI 53/104 (51%). The calculated p-value
was below 0.001.
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lignancies and sepsis.
AKI significantly worsens the prognosis of hospitalized
patients [2,4]. This is particularly the case in the ICU
setting in which mortality can increase to 60% [4].
Meanwhile, sepsis / septic shock have been emerged as
the most frequent causes of AKI at the intensive care
unit [6]. The pathogenesis of sepsis-associated AKI is


























Figure 3 Incidence of AKI and mortality in tumor patients with versus
disease did not suffer from sepsis (54% - 115/212). The incidence of AKI wa
with a malignancy were diagnosed with sepsis (46% - 97/212). AKI occurrewith subsequent renal hypoperfusion on one hand, but
also systemic activation of the innate and aquired im-
mune response leading to inflammation of the kidney on
the other hand [6,13]. The processes involved shall not
be reviewed more in detail at the moment. However,
regarding the widespread host-initiated defense mecha-
nisms it becomes understandable that mortality rates
gradually increase with progressive severity of the septic














without sepsis. One-hundred and fifteen patients with a malignant
s 30% (35/115) and mortality was 22% (8/35). Ninety-seven patients
d in 69% (67/97), mortality was 67% (45/67).
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Bagshaw and colleagues showed higher AKI mortality
rates in septic shock with progressive deterioration of
renal function [15]. Interestingely, the authors did not
find higher incidences of AKI if the diagnosis of meta-
static solid organ cancer was made [15]. Patients with
non-solid hematologic malignacies on the other hand
developed AKI more frequently. Finally, Plataki and col-
leagues identified numerous AKI risk factors in septic
shock, including delayed initiation antibiotic therapy,
intra-abdominal sepsis, and blood product transfusion
[16]. A detailed metaanalysis about AKI risk factors in
sepsis was published by Cartin-Ceba et al. in 2012 [17].
As oposed to sepsis, there are generally less data avail-
able about epidemiology and outcome of AKI in tumor
patients. A recently published cross-sectional analysis of
prospectively collected data revealed an AKI incidence
of 12% in the latter group of patients [18]. In this study
AKI risk was significantly correlated with pre-existing
diabetes, hyponatremia, intravenous contrast media ad-
ministration, chemotherapy, and antibiotics. Sepsis in
contrast was not identified as risk factor. Another study
evaluated predictors of hospital mortality in critically ill
cancer patients according to the severity of renal dys-
function. AKI, as defined by the RIFLE criteria [19],
occurred in 54.2% and mortality increased with progres-
sion from ‘R’ to ‘F’ [20]. The results from our study are
more or less in line with data from the literature: inci-
dences of AKI were higher in sepsis than in non-septic
patients, survival in sepis-associated AKI was lower than
in AKI without sepsis or in sepsis without AKI. Frequen-
cies / survival of AKI were higher / lower if a malignant
disease was present. Somehow surprising was the obser-
vation of comparable mortality rates in non-tumor, non-
septic patients with versus without AKI (15%). One
might argue that due to the absence of sepsis, the overall
morbidity of these patients was lower than in septic
individuals.
The first new aspect in our study is related to the con-
incidence of tumor and sepsis and to survival rates of
these patients if dialysis therapy became mandatory. In
the latter group, mortality increased to almost 70%
(66%) which once had been reported as the average mor-
tality of AKI patients in the 1970s [21]. A second new
aspect is related to mortality in tumor patients with
sepsis and AKI, regarding the respective nature of the
malignant disease. If a non-solid tumor was diagnosed,
mortality was 100% as compared to patients with non-
solid malignant disease. In those patients mortality was
significantly lower (56%). To our knowledge, this obser-
vation has never been reported before and we can only
speculate whether non-solid tumors affect the outcome
by mechanism related to the disease per se or if the
poor outcome results from more aggressive therapeuticinterventions. In summary, we conclude that prognosis
of tumor patients with AKI and sepsis is very poor. We
are well aware of the fact that due to the retrospective
and single center-based character of our study, conclu-
sions must be drawn with caution. Thus, further pro-
spective analyses are urgently needed.
Conclusions
We conclude that prognosis of tumor patients with AKI
and sepsis is very poor, with a mortality of approximately
70% if diaylsis therapy becomes mandatory. Mortality in-
creases even further if patients suffer from a non-solid
malignant disease, in this particular group almost 100%
of the patients die.
Key messages
 Sepsis and AKI significantly worsen prognosis of
tumor patients.
 Dialysis treatment in this group is associated with an
average mortality of 70%.
 Non-solid tumors are associated with mortality rates
of 100% if patients suffer from sepsis and AKI.
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